Abstract
Background
Food ladders are tools designed to facilitate home-based dietary advancement in children with food allergies through stepwise exposures to increasingly allergenic forms of milk and egg. Several studies have now documented safety and efficacy of food ladders. In 2021, we published a Canadian adaptation of the previously existing milk and egg ladders originating in Europe using foods more readily available/consumed in Canada. Our study adds to the growing body of evidence supporting food ladder use and provides safety and effectiveness data for our Canadian adaptation of the milk and egg ladders.
Methods
Surveys were distributed to families of children using the Canadian Milk Ladder and/or the Canadian Egg Ladder at baseline, with follow up surveys at 3 months, 6 months, and 12 months. Data were analyzed using REDCap and descriptive and inferential statistics are presented.
Results
One hundred and nine participants were started on milk/egg ladders between September 2020 and June 2022. 53 participants responded to follow up surveys. Only 2 of 53 (3.8%) participants reported receiving epinephrine during the study. Severe grade 4 reactions (defined according to the modified World Allergy Organization grading system) were not reported by any participants. Minor cutaneous adverse reactions were common, with about 71% (n = 10/14) of respondents reporting cutaneous adverse reactions by 1 year of food ladder use. An increasing proportion of participants could tolerate most foods from steps 2–4 foods after 3, 6, and 12 months of the food ladder compared to baseline.
Conclusion
The Canadian food ladders are safe tools for children with cow’s milk and/or egg allergies, and participants tolerated a larger range of foods with food ladder use compared to baseline.
Background
Cow’s milk and hen’s egg immunoglobulin E (IgE)-mediated food allergy (henceforth referred to as milk and egg allergy) are among the most prevalent allergies in childhood. The prevalence of these allergies in Canadian children is estimated at around 1.8 and 1.2 percent for milk and egg, respectively [1]. While the overall prognosis of both milk and egg allergy in children is generally favourable due to the relatively high likelihood of resolution, they can have a profound impact on quality of life and nutrition in young children, and avoidance of these ubiquitous foods can be difficult with accidental exposures being common [2,3,4,5,6,7,8,9]. Additionally, accurate laboratory predictors of resolution are lacking, and the diagnosis of resolution is dependent on oral food challenges which patients may have difficulty accessing in the real-world outside of controlled, research settings [10].
Food ladders are tools designed to guide a stepwise reintroduction of food allergens from extensively heated (i.e., baked) to less heated forms of protein. The advantages of using food ladders in the management of egg and milk allergic children is to facilitate home-based dietary expansion and encourage more rapid resolution of the food allergy. The first published food ladders originated in Europe and were originally intended for the management of non-IgE-mediated food allergy [11]. Several iterations of the milk and egg ladders have since been published for the management of IgE-mediated milk and egg allergies, including our Canadian Food Ladders in 2021, which adapted concepts from the European food ladders using foods readily available in the Canadian context (Supplementary materials 1 and 2) [12,13,14,15,16,17]. A handful of small studies have now been published to date on safety and efficacy of egg and milk ladders, utilizing European or Australian versions of the food ladders [13,14,15, 17,18,19]. This study sought to report the safety of the Canadian Food Ladders and to document dietary expansion through food ladder use, adding to the small but growing body of evidence supporting food ladders in the management of IgE-mediated milk and egg allergy.
Methods
Ethics approval
was granted through the UBC C&W Research Ethics Board. The previously used European milk and egg ladders were adapted by our team with foods more readily available/consumed in Canada [12]. Foods included and their order of appearance on the ladders were inspired by existing food ladders, and modifications were agreed upon by consensus opinion and best available evidence. Food ladders were then provided to Canadian allergists electronically and also distributed through the Canadian Society of Allergy and Clinical Immunology for more widespread participation. A participation link and QR code were embedded on the food ladders as well as on a coversheet, and versions of the ladders were provided in French and English. Participating allergists determined patient suitability to receive a food ladder for the advancement of diet as per typical individual practice. Included patients were under 18 years of age with allergist-diagnosed egg or milk allergy. Participation was voluntary and consent was obtained from participants (parents of children who were prescribed a food ladder), followed by a baseline survey establishing patient demographics such as age, atopic history, and foods tolerated prior to commencing ladder use (Supplementary materials 3). Follow up surveys were then distributed by email at 3, 6, and 12 months, assessing whether the patients were still using the Canadian Food Ladders, parental report of adverse reactions, symptoms associated with adverse reactions, and whether epinephrine was administered. Reactions were graded according to modified World Allergy Organization grading system [20]. A quality improvement approach was adopted, with regular monitoring of data for any concerning safety signals, and ability to improve our ladders in response to feedback. Data were analyzed using REDCap data software. Descriptive (e.g. frequencies) and inferential statistics were utilized.
Results
One hundred and nine parents (109) of children using food ladders completed our baseline survey between September 2020 and June 2022. Fifty-three participants completed any follow up survey, with 44, 35, and 14 parents completing the 3-month, 6 month, and 12 months follow up surveys, respectively. The mean age of children using a food ladder was 3 years 2 months, ranging from 7 months of age to 15 years. Thirty children received the Canadian Milk Ladder, 63 received the Canadian Egg Ladder, and 16 received both ladders (Table 1). All patients reported confirmed sensitization to milk and/or egg with skin prick testing or positive allergen-specific IgE.
46.8% of participants reported other food allergies, with peanut allergy being the most common. Atopic comorbidities were common, with eczema reported in 67.9% of children, asthma in 13.8%, and allergic rhinoconjunctivitis in 20.2%.
Symptoms reported at baseline with initial adverse reaction to milk and egg were similar, with the most common two symptoms reported being hives and angioedema (58% and 33% of patients reported hives and swelling, respectively, at initial reaction to milk, and 75% and 21% reported hives and swelling at initial reaction to egg) (Fig. 1A). 26.6% of all patients reported any history of epinephrine use due to adverse reactions to milk and/or egg. The population of participants who completed follow up surveys reported similar symptoms at initial adverse reaction to milk and/or egg compared to the entire study population that completed baseline surveys. 12/53 (22.6%) of participants who completed follow up surveys reported any history of epinephrine use due to adverse reactions to milk and/or egg.
At baseline, two-thirds (66.7%) of participants were tolerating at least one food from the milk ladder, and nearly three-quarters (73.3%) of participants were tolerating any food from the egg ladder (Fig. 2 and Fig. 3).
Increasing proportions of patients tolerated most step 2–4 foods at each follow up assessment. Isolated cutaneous adverse reactions were the most common adverse effect reported. About one fifth of patients reported any extracutaneous symptoms (Table 2). Severe Grade 4 reactions, defined by the modified WAO grading system, were not reported by any participants. Two of the 53 patients who completed follow up surveys (3.8%) indicated that a patient received epinephrine during the study. Both participants were egg allergic and experienced anaphylaxis while ingesting egg as per the egg ladder. Ages of the participants were 9 and 14 years old. One of these patients reported anaphylaxis with cough, rhinitis, and abdominal pain on the first day of ladder use to baked egg. The second patient reported anaphylaxis with cough, rhinitis, wheeze, conjunctivitis, hives, and angioedema to raw egg at 12 months follow up. Ten patients reported discontinuing using the food ladder (18.9%), 5 (9.4%) of which reported the reason for stopping was due to symptoms developing when eating foods from the ladder. Two patients did not specify a reason. One patient indicated that the ladder was too “difficult”- this is presumably related to adherence but was not specifically stated. Two patients were told by their physician to stop - this could be related to adherence or symptoms developing, but no specific reason given.
Discussion
Our data support food ladder use for the management of IgE-mediated milk and egg allergy in preschoolers. An increasing proportion of respondents generally tolerated foods from step 2–4 in each follow up assessment.
Our effectiveness data is relatively similar to outcomes suggested by previous studies. D’Art et al. published a study reporting on efficacy of cow’s milk ladders, and reported 65% of children who used a milk ladder were tolerating cooked cheese (lasagna) at 6 months (vs 53% of our cohort tolerating cooked cheese on pizza by 6 months), and 82% tolerating lasagna at 12 months (vs 100% in our cohort) [18]. D’Art et al found 54% of children in their study tolerated pasteurized milk or powdered infant formula by 12 months of ladder use (vs 40% in our cohort) [18]. Cotter et al reported 41% of their cohort tolerated scrambled egg at 6 months (vs 50% in our cohort), and 69% (vs 46% in our cohort) at 12 months using the Irish Food Allergy Network (IFAN) egg ladder [15].
Similar to preschool oral immunotherapy, we found mild cutaneous symptoms occurred fairly frequently in our cohort [21]. Isolated cutaneous symptoms occurred in 31.4% of respondents at 6 months, and 71.4% of respondents by 1 year. Epinephrine was administered to two patients for symptoms of anaphylaxis during our study. The two patients who received epinephrine were 9 and 14 years of age. One of the two patients who received epinephrine had a history of prior anaphylaxis to egg. Neither patient reported symptoms suggestive of severe grade 4 anaphylaxis as per the modified WAO grading system. Our initial Canadian food ladder publication already had stated that the ladders were intended for use in preschoolers with a history of mild reactions, but since a small subset of the surveys showed that patients with a history of anaphylaxis and/or those of school age were started on ladders, we decided to publish our proposed Food Ladder Safety Checklist 4 A’s (age, active or poorly controlled asthma, history of anaphylaxis, and adherence) to reinforce this further [12, 22]. The older age of the two patients who experienced anaphylaxis supports our recommended criteria for patient selection. No patients who met all 4 A’s were treated for anaphylaxis [22].
Compared to other existing ladders, the Canadian Food Ladders are relatively similar in terms of types of foods included and order of appearance. A decision was made to remove butter from the Canadian Milk Ladder due to variable and typically very low cow’s milk protein content across available butter products. Recently, De Vlieger et al suggested that boiled egg may be introduced earlier on the egg ladder, prior to pancakes and waffles based on lower ovalbumin content of hard-boiled egg [17]. In their cohort of 78 children, reported rates of adverse reactions were relatively low, however the largest proportion of adverse events occurred with hard-boiled egg ingestion in their study. In contrast, the foods most commonly reported to be associated with adverse reactions in our study was baked milk and egg, potentially attributable to the fact that the largest number of respondents consumed these foods during our study.
Our study had several limitations. Attrition was high by 12 months, making response bias a concern. However, the response rate at 3 and 6 months was satisfactory for a real-world setting outside of a controlled research environment. Similar studies suggest that many children may outgrow milk/egg allergies after longer than 12 months of ladder use, and therefore we were unable to capture complete course of treatment for our cohort. Additionally, epinephrine administration was used as an indicator of anaphylaxis, and anaphylaxis that was not appropriately treated with epinephrine would not be accounted for in our data. Finally, oral food challenges were not conducted at follow-up, and therefore effectiveness data is restricted to parental reports of tolerance of specific foods which may result in reporting bias due to variation in symptom perception. Strengths of our study included our real-world approach. Ladders were prescribed and managed by a wide range of allergists from across Canada, as per the prescribing allergists’ typical practice. Ongoing monitoring allowed us to make adjustments for safety and improve content, including the addition of the safety checklist and translation of the ladders from English to French.
Further research continues to be necessary for patients with IgE-mediated milk and/or egg allergies managed using food ladders. A larger sample size with control group or randomized controlled trial would be valuable to add strength to the results of this study. Kim et al. examined induction of sustained unresponsiveness in young children (mean age 7.3 years) who were tolerant to baked egg but not unbaked egg following 2 years of treatment with either egg OIT or with baked egg consumption. They found a clear benefit of OIT over baked egg consumption only with only 11.1% of baked egg tolerant children achieving sustained unresponsiveness compared to 43.5% of baked egg reactive participants who received OIT [23]. It is unclear at this point how food ladders might compare to OIT as no randomized controlled trials exist comparing oral immunotherapy (OIT) to food ladders for safety, efficacy, or quality of life measures. Whether food ladders lead to a permanent state of tolerance has also yet to be established and long term follow up data is required.
Food ladders as management tools for IgE-mediated milk and egg allergies in young children have the potential to ease health care resource utilization through reducing the need for oral food challenges and potentially offering a home-based alternative for oral immunotherapy for some children. In addition, food ladders can offer flexibility and allows for more natural consumption of milk and/or egg compared to oral immunotherapy and may provide a lower cost alternative to oral immunotherapy in some circumstances. Our study reinforces the importance of appropriate patient selection for food ladder use, particularly with older age being a potential risk factor for adverse reactions.
Conclusions
Our study adds to a growing body of evidence supporting milk and egg ladder use. Our safety outcomes were similar to data published on previously existing European milk and egg ladders. Isolated cutaneous symptoms associated with food ladder use are relatively common, with severe symptoms or epinephrine administration being uncommon. In our cohort, both patients who received epinephrine were over the age of 6 years old, which supports our previously proposed criteria for patient selection for food ladder use. Therefore, our study supports the safety and appropriateness of milk and egg ladder use in those patients who meet the stringent criteria outlined in the 4As. Until further study can be completed revealing safety in other groups, including older patients, we caution against using these ladders in any patient who does not meet those stringent criteria
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- IgE:
-
Immunoglobulin E
- OIT:
-
Oral immunotherapy
References
Clarke AE, Elliott S, St-Pierre Y, Soller L, La Vieille S, Ben-Shoshan M. Temporal Trends in Prevalence of Food Allergy in Canada. J Allergy Clin Immunol Pract; April. 2020;8(4):1428–30.
Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137(4):1128–1137e1.
Sinai T, Goldberg MR, Nachshon L, Amitzur-Levy R, Yichie T, Katz Y, et al. Reduced Final Height and Inadequate Nutritional Intake in Cow’s Milk-Allergic Young Adults. J Allergy Clin Immunol Pract. 2019;7(2):509–15.
Protudjer JL, Jansson SA, Östblom E, Arnlind MH, Bengtsson U, Dahlén SE. Health-related quality of life in children with objectively diagnosed staple food allergy assessed with a disease-specific questionnaire. Acta Paediatr. 2015;104(10):1047–54. https://doi.org/10.1111/apa.13044. Epub 2015 Jul 6. PMID: 25983039.
Howe L, Franxman T, Teich E, Greenhawt M. What affects quality of life among caregivers of food-allergic children? Ann Allergy Asthma Immunol. 2014;113(1):69. https://doi.org/10.1016/j.anai.2014.04.016. 4e2.
Wood RA. The natural history of food allergy. Pediatrics. 2003;111(6 Pt 3):1631–7.
Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol. 2013;131(3):805–12. https://doi.org/10.1016/j.jaci.2012.10.060. Epub 2012 Dec 28.
Sicherer SH, Wood RA, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of egg allergy in an observational cohort. J Allergy Clin Immunol. 2014;133(2):492–9. https://doi.org/10.1016/j.jaci.2013.12.1041.
Fleischer DM, Perry TT, Atkins D, Wood RA, Burks AW, Jones SM, Henning AK, Stablein D, Sampson HA, Sicherer SH. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics. 2012;130(1):e25. Epub 2012 Jun 25.
Hsu E, Soller L, Abrams EM, Protudjer JLP, Mill C, Chan ES. Oral Food Challenge Implementation: The First Mixed-Methods Study Exploring Barriers and Solutions. J Allergy Clin Immunol Pract. 2020;8(1):149–156e1. https://doi.org/10.1016/j.jaip.2019.06.034. Epub 2019 Jul 10. PMID: 31301377.
Venter C, Brown T, Shah N, et al. Diagnosis and management of non-IgE-mediated cow’s milk allergy in infancy - a UK primary care practical guide. Clin Transl Allergy. 2013;3:23. https://doi.org/10.1186/2045-7022-3-23.
Chomyn A, Chan ES, Yeung J, Vander Leek TK, Williams BA, Soller L, et al. Canadian food ladders for dietary advancement in children with IgE mediated allergy to milk and/or egg. Allergy Asthma Clin Immunol. 2021;17:83. https://doi.org/10.1186/s13223-021-00583-w.
Gotesdyner L, Zeldin Y, Machnes Maayan D, Efron A, Stauber T, Maoz Segal R, et al. A structured graduated protocol with heat denatured eggs in the treatment of egg allergy. Pediatr Allergy Immunol. 2019;30:824–32. https://doi.org/10.1111/pai.13115.
Thomas L, Belcher J, Phillips R, Preece K, Bhatia R. Use of an egg ladder for home egg introduction in children with IgE-mediated egg allergy. Pediatr Allergy Immunol. 2021;32:1572–4. https://doi.org/10.1111/pai.13541.
Cotter S, Lad D, Byrne A, Hourihane JO. Home-based graded exposure to egg o treat egg allergy. Clin Transl Allergy. 2021;11:2–5. https://doi.org/10.1002/clt2.12068.
Leech SC, Ewan PW, Skypala IJ, Brathwaite N, Erlewyn- LajeunesseM, Heath S, et al. BSACI 2021 guideline for the management of egg allergy. Clin Exp Allergy. 2021;51:1262–78. https://doi.org/10.1111/cea.14009.
De Vlieger L, Nuyttens L, Matton C, Diels M, Verelst S, Leus J, Coppens K, Sauer K, Dilissen E, Coorevits L, Matthys C, Schrijvers R, Raes M, Bullens DMA. Guided Gradual Egg-Tolerance Induction in Hen’s Egg Allergic Children Tolerating Baked Egg: A Prospective Randomized Trial. Front Allergy. 2022;3:886094. https://doi.org/10.3389/falgy.2022.886094.
D’Art YM, Forristal L, Byrne AM, Fitzsimmons J, Van Ree R, et al. Single low-dose exposure to cow’s milk at diagnosis accelerates cow’s milk allergic infants’ progess on milk ladder programme. Eur J Allergy Clin Immunol. 2022;00:1–12.
Ball HB, Luyt D. Home-based cow’s milk reintroduction using a milk ladder in children less than 3 years old with IgE-mediated cow’s milk allergy. Clin Exp Allergy. 2019;49(6):911–20.
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010;125:569–74. 574e1-574.e7.
Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, Lidman PG, Yeung J, Vander Leek TK, McHenry M, Wong T, Cook VE, Hildebrand KJ, Gerstner TV, Mak R, Lee NJ, Cameron SB, Chan ES. First Real-World Safety Analysis of Preschool Peanut Oral Immunotherapy. J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2759–2767e5. https://doi.org/10.1016/j.jaip.2019.04.010. Epub 2019 Apr 17. PMID: 31002957.
Chua GT, Chan ES, Yeung J, et al. Patient selection for milk and egg ladders using a food ladder safety checklist. Allergy Asthma Clin Immunol. 2022;18:51. https://doi.org/10.1186/s13223-022-00696-w.
Kim EH, Perry TT, Wood RA, Leung DYM, Berin MC, Burks AW, Cho CB, Jones SM, Scurlock A, Sicherer SH, Henning AK, Dawson P, Lindblad RW, Plaut M, Sampson HA, Consortium for Food Allergy Research (CoFAR). Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. J Allergy Clin Immunol. 2020;146(4):851–862e10. Epub 2020 Jun 12. PMID: 32535135; PMCID: PMC7554054.
Acknowledgements
We would like to acknowledge the following allergists for their contribution to the development of the Canadian Food Ladders: Drs Stuart Carr, Stephanie Erdle, Victoria Cook, Tom Gerstner, Kyla Hildebrand, Sandy Kapur, Sara Leo, Per Lidman, Mary McHenry, Gregory Rex. We would also like to acknowledge Dr Jonathan Hourihane for inspiring our group’s early discussions regarding implementing food ladders in our practices in Canada.
Funding
Not applicable
Author information
Authors and Affiliations
Contributions
AC was a major contributor in writing the manuscript and contributed to conceptual development. ESC, JY, TV, LS, EA, RM and TW were main developers of the concept of the Canadian Food Ladders and determining the final content and recommended use. BW contributed intellectually with the ladder development and designed the ladders. In addition to her role above, TW played a major role in developing the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
Ethics approval was granted from the Research Ethics Board at the University of British Columbia (UBC C&W number H19-04044).
Consent for publication
Not applicable.
Competing interests
The other authors declare that they have no competing interests. ESC has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK; is a member of the healthcare advisory board for Food Allergy Canada; and was co-lead of the CSACI oral immunotherapy guidelines. JY received speaking honoraria from UBC CPD, Sanofi, AstraZeneca, Pfizer, Stallergenes Greer, Novartis, Pediapharm, Medexus Pharma. She has served on advisory/consultancy committees for Sanofi, Pfizer, HealthLinkBc, Stallergenes Greer, and LEO Pharma. TV has served on advisory boards and received honoraria from Aralez, Bausch Health, and Pfizer. EA served on the Healthcare advisory board, and Food Allergy Canada. She received moderator/speaker fees from Novartis, GSK, and AstraZeneca. RM was a moderator/speaker for Astra Zeneca, Pediapharm, and Novartis. He has been on advisory boards for Sanofi, and ALK.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material
![](http://media.springernature.com/lw1/springer-static/esm/art%3A10.1186%2Fs13223-023-00847-7/MediaObjects/13223_2023_847_MOESM1_ESM.png)
![](http://media.springernature.com/lw1/springer-static/esm/art%3A10.1186%2Fs13223-023-00847-7/MediaObjects/13223_2023_847_MOESM2_ESM.png)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chomyn, A., Chan, E.S., Yeung, J. et al. Safety and effectiveness of the Canadian food ladders for children with IgE-mediated food allergies to cow’s milk and/or egg. Allergy Asthma Clin Immunol 19, 94 (2023). https://doi.org/10.1186/s13223-023-00847-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13223-023-00847-7